Barbara Byers
Psychiatry · New York, NYNPI 1659498947
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,237 of the $5,895 with a category attached, or 71.9%. 18 manufacturers reported payments, led by Biogen at 28.1% of the total. 2025 is the largest year on record at $2,170, 2.3 times the $958 reported in 2019. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$2K
- Lundbeck LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$742
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$462
- Sunovion Pharmaceuticals Inc.$408
- AbbVie$388
- plus $1K from 12 others
What the payments were for
- Consulting fees$1,65828%
- Food & beverage$4,23772%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 1 | $1,658 |
| Lundbeck LLC | 65 | $1,128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $742 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $462 |
| Sunovion Pharmaceuticals Inc. | 20 | $408 |
| AbbVie | 25 | $388 |
| Otsuka America Pharmaceutical, Inc. | 16 | $274 |
| Bausch Health US, LLC | 9 | $175 |
| Avanir Pharmaceuticals, Inc. | 11 | $159 |
| Supernus Pharmaceuticals, Inc. | 8 | $158 |
| Axsome Therapeutics, Inc. | 4 | $107 |
| Sage Therapeutics, LLC | 3 | $61 |
| Vertical Pharmaceuticals, LLC | 3 | $45 |
| Neos Therapeutics, LP | 2 | $36 |
| Johnson & Johnson | 2 | $33 |
| Tris Pharma Inc | 1 | $25 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Adlon Therapeutics L.p. | 1 | $17 |
How this compares
$5,895 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $1,094 |
| Bupropion XlBupropion Hcl | 20 | $943 |
| Sertraline Hcl | 21 | $360 |
| Trazodone Hcl | 13 | $112 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New York
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.